跳至主要内容
临床试验/DRKS00032573
DRKS00032573尚未招募不适用

Development of a marker panel for the individualized bDMARD therapy of psoriatic arthritis (Integrate-PsA) - Integrate-PsA

Ruhr-Universität Bochum0 个研究点目标入组 100 人开始时间: 2024年3月19日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Diagnosis of active PsA (psoriatic arthritis)
  • - No MDA status (minimal disease activity) after at least 3 months of MTX (methotrexate) treatment
  • - Clinical indication for treatment escalation from MTX to a b-DMARD (biologic disease-modifying antirheumatic drug)
  • - Switch to one of the following three biologic classes: TNFi (tumour necrosis factor inhibitor), IL17i (Interleukin 17 Inhibitor) and IL23i (Interleukin 23 Inhibitor)

排除标准

  • - Non-response or intolerance to MTX (methotrexate)

研究者

相似试验